New Therapies for Ovarian Cancer

David M. O’Malley

doi:10.6004/jnccn.2019.5018

Jump to Content

New Therapies for Ovarian Cancer

Author:

David M. O’Malley

David M. O’Malley
Search for other papers by David M. O’Malley in
Current site
Google Scholar
PubMed

View More View Less

Volume/Issue:: Volume 17: Issue 5.5

Online Publication Date:: May 2019

DOI:: https://doi.org/10.6004/jnccn.2019.5018

Restricted access

Get Citation Alerts

After 3 to 4 decades of stagnation, several new options are available for the treatment of ovarian cancer, some of which produce longer survival compared with historical controls. Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence. Indications for bevacizumab have been extended, and there are now multiple combination chemotherapy regimens that include bevacizumab as part of initial treatment and as an option for maintenance therapy in select patients, both for first-line primary/adjuvant chemotherapy and for treatment of recurrent or refractory disease.

Correspondence: David M. O’Malley, MD, Gynecology Oncology Phase I Program, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, 310 West 10th Avenue, Columbus, OH 43210. Email: omalley.46@osu.edu

Print
Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://jnccn.org/abstract/journals/jnccn/17/5.5/article-p619.xml
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully